ERBB2 and gastric cancer: In Her2-positive gastric cancer, the use of anti-PD-1/Her2 bispecific antibodies in organoid models has demonstrated the induction of gasdermin B-cleavage and pyroptosis, offering promising therapeutic avenues [82].